Vaccine Adjuvants Market Research, 2032
The global vaccine adjuvants market was valued at $1 billion in 2022, and is projected to reach $1.5 billion by 2032, growing at a CAGR of 4% from 2023 to 2032. According to the U.S. Department of Health and Human Services worldwide, 1 in 5 children lack access to necessary immunizations. According to U.S. Department of Health and Human Services every year, childhood vaccinations save 4 million lives globally. Between 2021 and 2030, vaccinations could avert more than 50 million lives. Moreover, according to World Health Organization the number of "zero-dose children," or children who do not receive any vaccinations, decreased from 18.1 million in 2021 to 14.3 million in 2022, almost returning to the pre-pandemic 2019 level of 12.9 million. Further, the growth of the vaccine adjuvant market is due to an increase in the incidences of infectious diseases, growing emphasis on preventative healthcare, and expanding vaccine development.
An adjuvant is a substance added to a vaccine with the intention of boosting the vaccine's immunological response. Certain vaccinations contain an adjuvant, which is a substance that strengthens the immunological response in recipients. By inducing a more robust and long-lasting immune response, adjuvants primarily aim to increase the efficacy of vaccinations by providing improved protection against the intended infectious agent. The necessity for adjuvants to increase vaccine effectiveness is subsequently driven by the increased demand for vaccines resulting from this emphasis on proactive healthcare methods. In May 2023, UK specialty chemicals company Croda signed partnership agreements with US companies Amyris and Botanical Solutions Inc (BSI) to source sustainable vaccine adjuvants.
Key Takeaways of Vaccine Adjuvants Market Report
- On the basis of type, the immunostimulants segment dominated the vaccine adjuvants market size in terms of revenue in 2022. However, the vehicles segment is anticipated to register the fastest CAGR during the forecast period.
- On the basis of disease, the infectious disease segment accounted for the largest share in terms of revenue in 2022 and is also anticipated to register the fastest CAGR during the forecast period.
- On the basis of application, the commercial segment dominated the vaccine adjuvants market share in terms of revenue in 2022 and is anticipated to register the fastest CAGR during the forecast period.
- On the basis of region, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the fastest CAGR during the forecast period.
Market Dynamics
The major factor that drives the vaccine adjuvants market growth is an increase in the number of infectious diseases. The need for efficient vaccines is fueled by the increased prevalence of infectious diseases, especially those caused by new and re-emerging microorganisms. Thus, adjuvants for vaccines are essential for increasing the effectiveness of vaccinations, giving them greater potency and powerful protection against pathogens. Furthermore, with the growing emphasis on preventive healthcare, vaccination is being prioritized as the main method of illness prevention in this global trend towards preventive healthcare, especially after the COVID-19 pandemic.
The particular molecules known as antigens are those against which the immune system launches an attack because it perceives them as foreign substances. Adjuvants stimulate the immune system in a number of ways, including by encouraging immune cell activation, increasing antigen persistence at the injection site, and adjusting the immunological response to produce a stronger, longer-lasting reaction. An expanding pipeline of novel vaccines targeted at treating a variety of diseases is the product of ongoing research and development activities in the field of vaccination. As more vaccines advance into the development stage, there is a greater need for adjuvants to increase their efficacy, which is driving the vaccine adjuvants market opportunity to rise.
Advances in immunology and biotechnology have been crucial in the field of adjuvant design, resulting in the development of novel and more sophisticated adjuvants. A major factor driving the market's growth is the discovery of adjuvants with enhanced immunostimulatory properties that are not only safer but also more powerful. Moreover, the vaccine adjuvants market has expanded significantly in emerging markets owing to the development of healthcare infrastructure and increased R and D activities. Rapid urbanization and economic growth in countries such as China and India have created substantial opportunities for vaccine adjuvant manufacturers to cater to the needs of these growing markets, thus boosting the vaccine adjuvants market forecast. However, challenges such as high investment, R and D costs associated with vaccine adjuvants, and regulatory and safety concerns may pose hindrances to widespread adoption, thereby restraining the market growth.
Segmental Overview
The vaccine adjuvants market is segmented into type, disease, application, and region. On the basis of type, the market is bifurcated into immunostimulants and vehicles and mucosal adjuvants. The immunostimulants segment is further segmented into toll like receptor and others. As per disease, the market is divided into infectious diseases and cancer. The infectious diseases segment market is further segregated into hepatitis and others. On the basis of application, the market is classified into research and commercial.
Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (India, China, Japan, Australia, South Korea, and rest of Asia-Pacific), and Latin America (Brazil, Argentina, Colombia and rest of Latin America) and Middle East and Africa (GCC, South Africa, North Africa and rest of LAMEA).
By Type
The immunostimulants segment accounted for the largest vaccine adjuvants market share in terms of revenue in 2022, owing to the widespread availability of immunostimulant adjuvants, and their enhanced immune responses as they directly act on the immune cells to increase responses to antigens. On the other hand, in the immunostimulants sub-segments, the toll like receptor segment dominated the market in 2022 owing to commercial approval and availability of the same and so it is widely adopted, however, other segment is anticipated to drive the market owing to research and development for other types of immunostimulants. However, the vehicle segment is expected to attain the highest CAGR during the forecast period owing to increasing adoption of mineral salt-based adjuvants, technological advancements contribute significantly to the heightened demand in vehicle and mucosal adjuvants.
By Disease
The infectious disease segment accounted for largest vaccine adjuvants market size in terms of revenue in 2022, and is also expected to register fastest CAGR during the forecast period, owing to rapid development of vaccines for the growing infectious disease population, and emerging viral threats contributes significantly to the dominance and growth of this segment. On the other hand, in the infectious disease sub-segment, hepatitis segment dominated the market in 2022 owing to wide availability of commercially available adjuvant based vaccines, and others segment is expected to grow with the highest CAGR owing to emerging viral threats which contributes significantly to the growth of this segment.
By Application
The commercial segment accounted for the largest vaccine adjuvants market share in 2022, and is also expected to grow with the highest CAGR in the forecast period owing to governmental approval for various types of adjuvants for vaccine development, thus leading to a higher demand for adjuvants to improve immune response. Moreover, higher adoption of vaccine adjuvant technologies across diverse applications, and favorable government policies drive the growth of the market.
By Region
The vaccine adjuvants market is analyzed across North America, Europe, Asia-Pacific, Latin America, Middle East and Africa. North America dominated the global vaccine adjuvants market in terms of revenue in 2022, driven by its advanced healthcare infrastructure, substantial investments in R and D, and the presence of major industry players offering vaccine adjuvants, owing to its commercial as well research based high adoption. Further, ongoing technological advancements for other disease application have contributed to market growth in the region.
On the other hand, Asia-Pacific is expected to register the fastest CAGR during the forecast period. This is attributed to rise in population suffering from infectious diseases, escalating healthcare expenditures, and rapid technological advancements that significantly contribute to market expansion. The rise in incidence of chronic diseases and infectious conditions in countries such as China, India, and Southeast Asian nations has spurred the demand for vaccine adjuvants.
For the vaccine adjuvants market, rising awareness and the growth of immunization programs in emerging nations provide profitable prospects. Advanced adjuvant technologies are becoming more and more necessary as these regions work to improve their healthcare infrastructure and meet the growing demand for vaccinations that are both affordable and effective.
Furthermore, the expansion of the biopharmaceutical sector in the Asia-Pacific region, coupled with a focus on innovative therapies and development, has accelerated the adoption of vaccine adjuvants technologies. Initiatives aimed at enhancing healthcare accessibility and affordability, have further propelled market growth across the region.
Moreover, the substantial population within the Asia-Pacific region presents an extensive pool of individuals for clinical trials and research investigations, thereby amplifying the demand for vaccine adjuvants solutions in both preclinical and clinical settings. Governmental support for scientific research initiatives, combined with collaborations between local and global players, is propelling innovation in vaccine adjuvants technologies, positioning Asia-Pacific as an exceptionally dynamic and promising market during forecast period.
Asia-Pacific offers profitable opportunities for key players operating in the vaccine adjuvants market, thereby registering the fastest growth rate during the forecast period, owing to the developments in healthcare infrastructure, rise in R and D activities, as well as well-established presence of domestic companies in the region. In addition, the rise in contract manufacturing organizations within the region provides great opportunity for new entrants in this region.
There is potential for ground-breaking breakthroughs in the ongoing adjuvant technology and immunology research and development efforts. More creative approaches to the design and development of unique adjuvants may provide new opportunities for market participants and result in the production of vaccines with higher efficacies. Adjuvanted vaccine development can be aided by partnerships between government agencies, academic institutions, and pharmaceutical businesses. Collaborations provide a cooperative strategy for addressing challenges, sharing expertise, and accelerating the release of novel vaccine formulations.
Competition Analysis
Competitive analysis and profiles of the major players in the vaccine adjuvants market, such as Adjuvatis, Dynavax Technologies Corporation, GSK, Croda International, Novovax, SEPPIC, Agenus Inc, Invivogen, SPI Pharma, and Aurorium are provided in the report. Major players have adopted partnership and business expansion as key developmental strategies to improve the product portfolio of the vaccine adjuvants market.
Recent Development in Vaccine Adjuvants Industry
In May 2023, UK specialty chemicals company Croda signed partnership agreements with US companies Amyris and Botanical Solutions Inc (BSI) to source sustainable vaccine adjuvants.
Furthermore, in March 2022, Croda received an exclusive license to commercialize SSI CAF vaccine adjuvants. SSI cationic adjuvants have significant potential for future vaccine development, thereby boosting the vaccine adjuvants industry.
Key Benefits for Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccine adjuvants market analysis from 2022 to 2032 to identify the prevailing vaccine adjuvants market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the vaccine adjuvants market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global vaccine adjuvants market trends, key players, market segments, application areas, and market growth strategies.
Vaccine Adjuvants Market Report Highlights
| Aspects | Details |
 Forecast period | 2022 - 2032 |
 Report Pages | 280 |
 By Type |
|
 By Disease |
|
 By Application |
|
 By Region |
|
 Key Market Players | Croda International Plc, GlaxoSmithKline plc, SPI Pharma, Inc., Adjuvatis, InvivoGen, SEPPIC, Aurorium, Agenus Inc., Dynavax Technologies Corporation, Novovax |
Analyst Review
The vaccine adjuvant market has witnessed a significant growth, primarily driven by the growth in infectious diseases and growing pharmaceutical industry. The increasing prevalence of chronic diseases, coupled with advancements in vaccine technologies, has driven the demand for vaccine adjuvants across the region. Countries such as China, Japan, and India are experiencing a surge in healthcare investments, contributing to the expansion of healthcare infrastructure. Moreover, the rising awareness and the importance of preventive healthcare measures is fostering a growing demand for development of vaccine technologies.
In addition, the growing pharmaceutical industry in the developing region is expected to significantly contribute to the growth of the market. The growth of the pharmaceutical industry has resulted in increased research and development activities leading to a greater demand for vaccine adjuvants.
Furthermore, North America dominated the vaccine adjuvant market in terms of revenue in 2022 owing to advanced healthcare infrastructure, substantial investments in R and D, and the presence of major key players in the region. However, Asia-Pacific is expected to witness significant growth during the forecast period, owing to rise in availability of domestic market key players, surge in healthcare expenditure, and rise in population necessitating increased scrutiny in this region.
An adjuvant is a substance added to a vaccine with the intention of boosting the vaccine's immunological response.
The major factor that fuels the growth of the vaccine adjuvant market are growing emphasis on preventive healthcare, vaccination is being prioritized as the main method of illness prevention in this global trend towards preventive healthcare.
The immunostimulant segment is the most influencing segment in vaccine adjuvant market owing to advancements in immunostimulant formulations and increase in prevalence of infectious disease conditions requiring therapies further contribute to the segment growth.
Top companies such as Dynavax Technologies Corporation, GSK, Croda International, Novovax, Invivogen,held a high market position in 202
2. These key players held a high market position owing to the strong geographical foothold in North America, Europe, Asia-Pacific, and LAMEA.
The base year is 2022 in vaccine adjuvant market .
The market value of vaccine adjuvant market in 2032 is $1.5 billion
The forecast period for vaccine adjuvant market is 2023 to 2032
The total market value of vaccine adjuvant market is $1 billion in 2022.
Loading Table Of Content...
Loading Research Methodology...
